Immune Checkpoint Inhibitors as Switch or Continuous Maintenance Therapy in Solid Tumors: Rationale and Current State

Drs. Gupta and Brown review a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.

Shilpa Gupta, MD and Jason Brown, MD discuss trials with successful or negative results with maintenance therapy.

Drs. Brown and Gupta discuss key takeaways from the study and the impact these data are likely to have on clinical practice.

Two oncologists highlight practical considerations when choosing maintenance therapy.

Drs. Gupta and Brown share their thoughts on the next steps that can aid in uptake of maintenance therapy in different tumor types.

Shilpa Gupta, MD, and Jason R. Brown, MD, PhD, discuss a recently published paper by Grivas et al. (2019) on the use of checkpoint inhibitors for maintenance therapy to prolong the benefits of frontline therapy while minimizing toxicity in solid tumors.